Cotren

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cotren

The following table provides a rapid reference to the fundamental properties of Cotren, defining its identity and classification.

Property Description
Active ingredient Clotrimazol
Form Topical (Cream, Solution, Vaginal Tablet)
Pharmacological class Antifungal Agent (Antimycotic)
Common use Countering fungal infections
Origin Synthetic compound (Imidazole derivative)

Chemical Identity and Classification

Cotren is a specialized pharmaceutical preparation whose active ingredient is Clotrimazol, a substance derived from the imidazole chemical structure. This identity immediately places Cotren within the Pharmacological class of azole antifungal agents, also known as an antimycotic. Clotrimazol is a synthetic compound, manufactured to provide a targeted therapeutic effect. The inclusion of Clotrimazol on the WHO Model List of Essential Medicines confirms its established role in addressing fungal issues. This recognition underscores the drug’s long-standing, verified efficacy in its therapeutic area, which has been clinically recognized for its reliability across multiple decades of use.

Mechanism and General Purpose

The primary purpose of Cotren is to provide effective control and limitation of fungal organisms, including common yeasts and dermatophytes. The active substance operates by disrupting the structural integrity of the fungal cells, a mechanism that classifies its action as both fungistatic (inhibiting growth) and fungicidal (destroying cells). Clotrimazol possesses a broad spectrum of activity against various pathogenic fungal species, establishing its reliability for localized treatment. The general use is typically directed toward resolving superficial skin and mucosal fungal issues, a therapeutic area where the efficacy of azole compounds is recognized globally.

Forms for Topical Application and Differentiation

Cotren is designed for topical administration, meaning it is applied directly to the affected external areas rather than being ingested or injected. The medicine is presented in several specialized dosage forms—including a cream, a liquid solution, and a vaginal tablet—to facilitate the appropriate localized treatment across different affected tissues. Each form is a single-ingredient product delivered via a specific base/vehicle (such as a stabilizing cream base), which ensures the active Clotrimazol component is precisely delivered to the required site for optimal effect.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Cotren?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Cotren (Clotrimazol) as defined in government regulatory documents and official prescribing information.

Official Adverse Reactions and Frequencies

Adverse reactions associated with topical Clotrimazol preparations are frequently localized to the application site. Many reactions derived from post-marketing reports are classified with a Frequency Not Known (meaning the frequency cannot be estimated from the available data).

System Organ Class Commonly Reported Local Reactions Serious Reactions (Rare)
Skin and Subcutaneous Tissue Disorders Burning sensation, Stinging, Erythema (redness), Pruritus (itching), Skin irritation, Peeling, Pain at site.
Immune System Disorders Hypersensitivity reaction, Angioedema, Anaphylaxis.
Vascular and General Disorders Syncope (fainting), Hypotension (low blood pressure), Oedema (swelling).

Regulatory Safety Constraints

The medicine is formally contraindicated in individuals with a known hypersensitivity to the active ingredient, Clotrimazol, or to any of the excipients (non-medicinal ingredients) contained in the formulation. Official documentation states that the product should not come into contact with the eyes and is not intended for ophthalmic use.

Population-Specific Safety Statements

Safety statements exist for certain populations, reflecting the need for medical assessment or caution:

  • Pregnancy: The use of Clotrimazol is generally not recommended during the first trimester unless considered essential by a healthcare professional.
  • Lactation: Breastfeeding should be discontinued during treatment, as it is unknown if the substance is excreted in human milk.
  • Pediatrics: Safety and effectiveness have not been established in patients under two years of age in some official labels.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for the active ingredient in Cotren, Clotrimazol, states that acute toxicity and systemic overdose are unlikely following the product's intended topical application (cream, solution, or vaginal tablet). Systemic absorption is minimal, and acute overdosage would not be expected to lead to a life-threatening situation.

Official Overdose Manifestations and Actions

The primary regulatory focus for overdose is the accidental oral ingestion of the medicine. The prescribing information mandates specific actions and describes potential symptoms in this event:

Situation Documented Manifestation Required Action
Accidental Oral Ingestion Dizziness, Nausea, Vomiting Seek immediate medical attention or call a Poison Control Center

Supportive Measures and Antidote

When clinical symptoms of overdose become apparent after accidental swallowing, regulatory documents indicate that supportive measures such as gastric lavage should be considered. This procedural step should only be performed if the airway can be adequately protected. There is no specific antidote officially listed for Clotrimazol overdose.

Therapeutic Uses of Cotren

What Cotren Treats: Main Uses and Benefits

Cotren is commonly used to provide short-term, supportive symptomatic assistance across a range of applications, focusing on easing distress caused by acute symptom flare-ups. The active ingredient is indicated for various dermal and candidiasis-related infections. The medication may assist with managing the disruptive impact of symptoms to support general well-being.


Symptom Relief for Acute and Episodic Conditions

Cotren is relevant in situations involving certain distressing symptoms, where it helps address symptom clusters that may become intense or disruptive. The medication is generally applied for conditions characterized by episodic or fluctuating manifestations, including those presenting with localized discomfort and irritative states. It is commonly used when symptoms intensify and supportive relief is needed. The medicine may support the individual during difficult episodes by easing distress.

“It provides supportive relief when symptoms interfere with routine activities.”

Supportive Role in Maintaining Stability

The therapeutic domain is relevant in clinical settings that involve acute or unstable symptom patterns, especially those associated with heightened physiological activity or systemic imbalance. It provides short-term symptomatic assistance during phases of increased discomfort. Cotren contributes to improved comfort during periods of heightened symptoms and assists with maintaining a sense of stability when symptoms are more noticeable.

Quick Fact: Assistance with Physical Discomfort

Regulatory References

  1. Health Canada Product Monograph for Clotrimazole

Eligibility and Restrictions for Use

Who Can and Cannot Use Cotren?

The eligibility for using Cotren (topical Clotrimazol) is defined by official regulatory labeling, primarily focusing on patient allergies, age, and physiological status.


Contraindicated Populations and Restrictions

Category Official Regulatory Status
Absolute Contraindication Patients with known hypersensitivity (allergy) to clotrimazol or any other component (excipient) in the formulation [1.4, 1.5].
Application Site Ineligibility Not for ophthalmic use (eyes) or for the treatment of fungal infections of the nail or scalp [1.7, 2.2].

Age-Group and Physiological Eligibility

Category Official Regulatory Status
Adults and Older Adults Use is established and generally accepted [1.4, 1.2].
Pediatric Use Safety and effectiveness are established in children when used as indicated [1.4]. Topical products are not recommended for children under two years of age unless directed by a physician [3.1].
Pregnancy Restricted in the First Trimester (use only if clearly indicated). Use during the Second and Third Trimesters has not been associated with ill effects [2.2].
Lactation Use is generally accepted as systemic absorption is minimal following topical application [2.2].

Regulatory Basis of Use

Regulatory documentation establishes use for the general population but mandates exclusion for immunological reasons (hypersensitivity) and defines limitations based on application site and specific physiological states like early pregnancy. Due to negligible systemic absorption, topical use does not require specific dose adjustments for hepatic or renal impairment [1.2].

What should I know about interactions with other medicines?

The official interaction profile for Cotren is primarily defined by its topical and vaginal application, leading to a documented focus on specific local effects and a limited set of systemic pharmacokinetic concerns, as stated by regulatory authorities.

Pharmacokinetic and Systemic Interactions

Co-administration of the vaginal formulation of this medicine with oral Tacrolimus has been officially documented as potentially leading to increased plasma concentrations of Tacrolimus. This pharmacokinetic interaction necessitates the close monitoring of Tacrolimus plasma levels during concurrent therapeutic periods, as outlined in regulatory prescribing information.

Local Pharmacodynamic and Substance Interactions

Two distinct types of interactions related to local use are formally addressed in regulatory labeling:

  1. Antifungal Antagonism: Concurrent local application with polyene antifungal agents (such as Nystatin or Amphotericin B) may result in an antagonistic effect. This interaction is documented to cause a reduction in the therapeutic effectiveness of the polyene agent.
  2. Latex Degradation: The excipients in the vaginal formulation are officially stated to cause damage to latex contraceptives, including condoms and diaphragms. This physical interaction compromises the integrity of the device, which reduces its protective function. Due to this official restriction, the use of alternative contraceptive precautions is advised for at least five days following the application of the vaginal product.

Mechanism of Action

Cotren (Clotrimazole) acts as a non-competitive inhibitor of lanosterol 14-alpha-demethylase (CYP51), a cytochrome P450 enzyme in fungal cells. This enzyme is crucial for the biosynthesis of ergosterol, a principal sterol component of the fungal plasma membrane. The azole ring of Cotren binds to the heme iron of the CYP51 enzyme, blocking the demethylation of lanosterol. This inhibition results in the accumulation of toxic intermediate sterols, specifically 14-methyl-substituted sterols, within the fungal cell membrane. The incorporation of these aberrant sterols alters the structural and functional integrity of the membrane, increasing its permeability and fluidity. This cascade disrupts vital membrane-dependent processes, including nutrient transport and chitin synthesis regulation, leading to a system-level cessation of fungal cellular growth and division. Additionally, high local concentrations of the agent can exert direct damage to the membrane structure, independent of the sterol synthesis inhibition pathway.

Dosage and Administration Information

How to use Cotren

Cotren (Clotrimazol) is administered through non-systemic, localized routes. The application is determined by the specific form and site of infection, with administration primarily focused on the Topical (skin) and Intravaginal routes.


Official Routes, Dosing, and Frequency

The standard approach to using Cotren is based on the dosage form and target area.

Application Site Dosage Form & Strength Standard Regimen & Frequency Treatment Course Length
Skin (Topical) Cream or Solution (1%) Gently apply to the affected area twice daily (e.g., morning and evening). 2 to 4 weeks (up to 8 weeks for Tinea Pedis)
Vaginal Tablet (500 mg) One single 500 mg tablet inserted once daily at bedtime. Single day dose
Vaginal Cream (1%) or Tablet (100 mg) One applicatorful (Cream) or one 100 mg tablet inserted once daily at bedtime. 7 consecutive days

Administration Requirements and Duration

Treatment is typically maintained for the entire course, even if symptoms appear to resolve early. The duration for most skin infections ranges from 2 to 4 weeks.

Procedural Instructions:

  • Topical: The cream or solution must be gently massaged into the affected skin and the immediate surrounding area.
  • Vaginal: The dose is inserted deep into the vagina, preferably at bedtime to minimize leakage. The treatment course should generally not be interrupted during the menstrual period, and care must be taken with product contact and latex items.

Recent Clinical Evidence

Research Evidence Overview for Cotren (Clotrimazol)

This section summarizes the structure of the clinical research—including the types of trials, the outcomes measured, and the patient groups studied—that regulators consider when assessing the indication for Clotrimazol. This overview helps contextualize the available data but does not provide individual medical advice or treatment recommendations.


Evidence for use in Vaginal Yeast Infections (Vulvovaginal Candidiasis)

Research exploring how symptoms change over time in women with vaginal yeast infections primarily consists of short-term Randomized Controlled Trials (RCTs), as well as several Systematic Reviews and Meta-analyses. These studies were designed to examine how the medicine was evaluated for two main outcomes: the resolution of symptoms, known as clinical response, and the eradication of the causative yeast in laboratory tests, known as mycological clearance. Studies reported patterns of mycological clearance measured in the short term, and research highlighted changes in symptom scores observed during the study period.


Evidence for use in Superficial Skin Fungal Issues (Dermatophytoses and Cutaneous Candidiasis)

For superficial skin fungal issues like athlete's foot and ringworm, the evidence was evaluated in numerous short-term RCTs that often compared the topical cream to a non-active base (placebo) or to other established topical antifungal agents. These studies explored whether the medicine was associated with the clearance of the visible signs of infection and the measured changes in fungal presence. The follow-up durations were limited in most of these trials, meaning there is limited information available concerning the durability of the measured response after treatment is stopped.


Evidence in Special Populations and Uncertainties

Research has explored the use of Clotrimazol in several specific groups, including pregnant women and children (aged three years and older), with trials monitoring short-term symptom changes. Data for immunocompromised patients were also studied, particularly for oral fungal issues. However, long-term effects are not fully established, as the majority of evidence comes from studies observing responses over defined, short-term time intervals. Comparative evidence against all current treatment options is lacking, and results apply only to the populations studied.

Key Studies & References

  1. WHO Model List of Essential Medicines - Clotrimazole (Topical)
  2. Clotrimazole Product Monograph (Health Canada)

Frequently Asked Questions (FAQ)

Common questions about Cotren (FAQ)

Q: Is Cotren the same kind of drug as [similar drug name]?

A: Cotren’s active ingredient, clotrimazole, belongs to a group of medicines known as imidazole antifungal agents. Official product information classifies it this way based on its unique chemical structure and how it works to stop fungal growth. This classification helps define its core therapeutic group for comparing it with other medications.


Q: Are there any major diet restrictions while taking Cotren?

A: Official labeling for the topical and vaginal forms of Cotren does not specify any diet restrictions. Since the medicine is applied locally to the skin or vagina, rather than being taken systemically, food and drink are generally not a concern.


Q: What happens if I forget to take a dose of Cotren?

A: If a dose of Cotren is missed, regulatory guidance generally describes taking it as soon as possible. However, if it is almost time for the next scheduled dose, the labeling describes skipping the missed dose and resuming the regular schedule. Official information advises against taking a double dose to make up for a missed one.


Q: Do I need to take Cotren with food?

A: Official labeling for the topical and vaginal formulations of Cotren does not include any requirements to take the medicine with food. The application instructions focus on applying the product directly to the affected area or inserting it vaginally.


Q: Does Cotren contain sulfa?

A: No, Cotren does not contain sulfa. The active ingredient, clotrimazole, is an imidazole derivative. It is a synthetic compound and is not chemically related to the sulfonamide (sulfa) class of drugs.


Q: How is Cotren removed from the body?

A: The small quantities of Cotren that are systemically absorbed following topical or vaginal use are primarily broken down (metabolized) in the liver and subsequently leave the body through the bile.


Q: What happens if I stop taking Cotren suddenly?

A: Official regulatory guidance emphasizes using the medication for the full prescribed treatment time. Regulatory information indicates that stopping treatment early, even if symptoms appear to improve, may be associated with the recurrence of infection.


Q: Are there any warnings about driving or operating machinery while on Cotren?

A: Official regulatory labels for topical and vaginal clotrimazole do not generally include specific warnings about driving or operating heavy machinery. The drug's local method of application and minimal systemic absorption mean such warnings are typically not required.


Q: Does alcohol interact with Cotren?

A: Official patient information for topical clotrimazole does not list a specific interaction with alcohol. Due to the minimal systemic absorption of the topical and vaginal products, major interactions with substances like alcohol are typically not a concern.


Q: Is Cotren available over the counter?

A: Yes, many topical forms of clotrimazole, the active ingredient in Cotren, are widely available as Over-The-Counter (OTC) medicines. This means a prescription is generally not required to obtain them, although availability may vary by location.


Q: Is Cotren addictive or habit-forming?

A: No, Cotren is not considered addictive or habit-forming. The medication is classified as an antifungal agent, and regulatory documents do not list any properties related to dependence or addiction.


Q: Is Cotren typically covered by insurance?

A: Coverage for medicines like Cotren is managed by individual health plans and local regulations. While the active ingredient is often widely covered due to its essential medicine status, some jurisdictions may apply special criteria (e.g., for patients with diabetes or circulatory conditions) for coverage of certain formulations.


Q: How long does Cotren stay in your system?

A: After being applied vaginally, the drug can stay at effective concentrations locally in the vagina for up to 3 days. Systemic absorption is minimal; therefore, the amount that reaches the rest of the body is very small and is quickly metabolized.


Q: Is Cotren used to treat inflammation?

A: Clotrimazole, the active ingredient in Cotren, is used solely to treat fungal infections. It is not classified as an anti-inflammatory medicine. Clotrimazole alone is not classified as an anti-inflammatory medicine; when relief from inflammation is desired, it is sometimes combined with a corticosteroid in specific products.


Q: Can Cotren be split or crushed?

A: Vaginal tablets are designed to be inserted whole. Official product information for these forms describes that they should not be cut, crushed, or chewed to maintain the intended function.


Q: Does Cotren cause sun sensitivity?

A: Official labeling advises caution regarding sun exposure. If a condition called photosensitivity (increased sensitivity to sunlight) develops during the use of clotrimazole, regulatory documents describe that the treatment is advised to be discontinued.


Q: Does Cotren need a special prescription?

A: The topical forms of Cotren are generally available as Over-The-Counter (OTC) products. This means a special prescription is usually not needed to purchase the medicine.


Q: Can I use Cotren if I have diabetes?

A: Official regulatory information describes that patients experiencing frequent vaginal yeast infections (e.g., once a month) should be evaluated by a healthcare professional before using the product, as this may indicate an underlying condition like diabetes.


Q: Is Cotren considered a long-term medication?

A: Cotren is primarily used for short-term treatment courses lasting from a single day up to 8 weeks, as defined in official prescribing information. Long-term use is not typically required, and regulatory research focuses on short-term outcomes.


Q: Are there any specific organs that Cotren affects?

A: Cotren is mainly a localized treatment, meaning it acts primarily on the skin or mucosal surface where it is applied. Due to minimal systemic absorption, it generally does not affect major internal organs, though rare systemic reactions are documented.


Q: Does Cotren interact with birth control pills?

A: Official warnings focus on the vaginal formulation’s excipients causing damage to latex contraceptives (condoms and diaphragms). The regulatory labeling does not specifically document an interaction between topical/vaginal clotrimazole and systemic hormonal (oral) birth control pills.


Q: What are the requirements for monitoring while taking Cotren?

A: General monitoring for topical use is typically focused on symptom resolution and watching for local adverse reactions. However, if Cotren is used alongside certain other medicines, such as oral Tacrolimus, official documents require close monitoring of blood levels of the interacting drug.


Q: How does Cotren affect the immune system?

A: Cotren’s primary action is against fungal cells by disrupting their structure. While the drug can trigger rare allergic reactions (hypersensitivity, anaphylaxis) which involve the immune system, regulatory labeling does not suggest the drug has a systemic suppressive effect on the human immune system.

How should Cotren be stored and disposed of?

The storage and disposal of Cotren, which contains the active ingredient Clotrimazol, must adhere strictly to the conditions defined in official regulatory labeling.

Storage Requirements

The product must be stored at room temperature, generally between 15 C and 30 C. It is mandatory to keep the container tightly closed and store the medicine in its original container, protected from excessive heat and moisture. To prevent damage to the formulation, the product must not be frozen.

Child Safety

Consistent with official regulatory standards for all medicines, Cotren must be stored out of the sight and reach of children to prevent accidental exposure.

Disposal Instructions

Unused or expired Cotren must be disposed of according to local regulations. Consumers are advised to utilize drug take-back programs where available, as the product must not be thrown into wastewater or flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cotren found in:

A-Z Index: